InDex Pharmaceuticals AB på First North gör en nyemission på 37,5 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor

Shares in InDex Pharmaceuticals Holding AB are currently priced at SEK1.8. At that level they are trading at 0.137% discount to the analyst consensus target price of 0.00. Analysts covering InDex Pharmaceuticals Holding AB currently have a consensus Earnings Per Share (EPS) forecast of -1.5 for the next financial year.

2021-03-12 · InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the 2021-03-12 · 12 mars 2021 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att ägarlistan på hemsidan uppdaterats med ägarinformation per 26 februari 2021. InDex är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar med stora medicinska behov av nya behandlingsalternativ. Bolagets Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) interim report January - September 2020. Publicerad: 2020-11-25 (Cision) Index Pharmaceuticals: InDex Pharmaceuticals avser att genomföra en fullt garanterad företrädesemission om cirka 500 miljoner kronor för att finansiera fas III-utveckling av cobitolimod Köp aktien InDex Pharmaceuticals Holding AB (INDEX).

Index pharmaceuticals placera

599 likes · 3 were here. InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för inflammatorisk tarmsjukdom som kan hjälpa patienter tillbaka till ett InDex Pharmaceuticals får nytt patent i Europa ons, jun 26, 2019 15:50 CET. 26 juni 2019 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att ett nytt användningspatent för läkemedelskandidaten cobitolimod har beviljats av det europeiska patentverket EPO. 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. InDex Pharmaceuticals AB,556704-5140 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för InDex Pharmaceuticals AB Should you invest in InDex Pharmaceuticals Holding (OM:INDEX)? Adequate balance sheet and overvalued. Last updated 2021/03/19 19:35 InDex Pharmaceuticals AB, Stockholm. 606 likes · 19 talking about this · 3 were here.

InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. Shareholders in InDex Pharmaceuticals Holding AB as of February 26, 2021.

InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe 07 April 2021 - Other press release; InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis 30 March 2021 - Other press release; InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General

Our efforts have been to come out with safe drugs with stringent checks on safety parameters, which also happens to be our forte. Read More Intresserad av ämnet Index Pharmaceuticals? Här hittar du samtliga artiklar, kommentarer och analyser om Index Pharmaceuticals från Dagens industris redaktion.

3 Dec 2015 Abstract. Background: Lenalidomide with dexamethasone (Rd) is a standard of care for patients with previously untreated multiple myeloma.

This link will take you to a site maintained by a third party who is solely responsible for the content of that site. Orexo provides this link as a service to website visitors. Tesomet has the potential to significantly reduce weight and body mass index (BMI), and treat debilitating hyperphagia in these severe, rare and highly underserved eating disorders. By pursuing such orphan indications, we are creating a unique opportunity to develop and bring our own product to the market,” says Jørgen Drejer, CEO of Saniona.

avanza.se/placera/forum/forum/enorama-pharma.0.html. 5 januari 2018 Gilla (2) 20. jan 2017 Medicinalkoncernen Zealand Pharma har fået løftet sit kursmål hos Nordea til 130 kr. fra 106 kr. Anbefalingen af aktien, der torsdag faldt 3,6 pct The bullish FAS seeks returns corresponding with triple the daily performance of the Russell 1000 Financial Services Index while the bearish FAZ looks to 10 May 2018 There were more than 25,000 late cancelled operations from January to March - the highest since records began in the mid-1990s. Redeye reiterates its positive stance on InDex Pharmaceuticals following today"s news that the European Patent Office has granted a patent Köp aktier i InDex Pharmaceuticals Holding - enkelt och billigt hos Avanza Bank.
Transport batemans bay

607 likes · 22 talking about this · 3 were here. InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för … Herbal Products / Herbal Extracts. Index has made a reputation for itself in trading and export of a wide range of herbal extracts and herbal products like calcium sennosides, herbal oil extracts, ginger extracts, which are used widely in the production of herbal medicine. 2021-04-07 InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry.

Latest Share Price and Events.
Vilken körkortsbehörighet måste du minst ha för att få köra denna fordonskombination

Aktieägare i de relaterade bolagen äger också aktier i InDex Pharmaceuticals Holding. Andelen 12 % anger hur många av Orphazyme-ägarna som även har InDex Pharmaceuticals Holding i sin portfölj. Informationen bygger på dagsaktuellt ägande hos Avanzas kunder och presenteras för bolag som ägs av minst 100 kunder.

Its portfolio includes cobitolimod and colitis. InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.

Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) interim report January - September 2020. Publicerad: 2020-11-25 (Cision) Index Pharmaceuticals: InDex Pharmaceuticals avser att genomföra en fullt garanterad företrädesemission om cirka 500 miljoner kronor för att finansiera fas III-utveckling av cobitolimod

Index Pharmaceuticals: InDex Pharmaceuticals presenterar på Redeye Growth Day 2020 26 maj 2020 - InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl. 15.50. Presentationen InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe 07 April 2021 - Other press release; InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis 30 March 2021 - Other press release; InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General InDex Pharmaceuticals updates shareholders list Fri, Mar 12, 2021 13:45 CET. March 12, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021. InDex Pharmaceuticals Holding AB (publ) är moderbolag i Koncernen som också omfattar InDex Pharmaceuticals AB och InDex Pharmaceuticals AB:s helägda dotterbolag, InDex Diagnostics AB. Shares in InDex Pharmaceuticals Holding AB are currently priced at SEK1.8.

Stable Share Price: INDEX is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 21% a week. Index Pharmaceuticals: InDex Pharmaceuticals presenterar på Redeye Growth Day 2020 26 maj 2020 - InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl. 15.50.